Arbovirus Testing Market Report Scope & Overview:

The Arbovirus Testing Market was valued at USD 1.31 Billion in 2025 and is expected to reach USD 2.01 Billion by 2035, growing at a CAGR of 4.36% from 2026–2035.

The global market for arbovirus testing is witnessing structural growth due to the increasing incidence of arthropod-borne viruses such as dengue, Zika, chikungunya, West Nile virus, and yellow fever, which together affect hundreds of millions of people annually in tropical, sub-tropical, and now even temperate climates as a result of climate change, which is causing mosquito breeding habitats to expand. According to the WHO, there were 6.8 million cases of dengue in early 2025 alone, up 24% compared to 2024, further emphasizing the growing trend in the epidemiology of arboviral infections that is prompting governments, hospitals, and diagnostic labs to build testing capabilities for such viruses. Timely and accurate diagnosis of arboviruses is crucial to differentiate between several clinical febrile presentations caused by arboviruses and help with managing patients, conducting surveillance of outbreaks, and conducting blood safety screening programs in endemic areas. Rapid innovation in the field of diagnostics is making it possible for molecular diagnostics firms to develop multiplex PCR tests to detect several arboviruses at once at a reduced cost per test.

The arbovirus testing market's 4.36% CAGR from 2026 to 2035 is due to the structural challenge of climate change, which has led to an increased geographic spread of the Aedes and Culex mosquitoes responsible for spreading the viruses in question into non-endemic temperate regions in Europe and North America, as well as improvements in diagnostic laboratory efficiency due to the adoption of multiplex molecular assay technology, and public health funding towards building out arbovirus surveillance capabilities, as part of the WHO Global Arbovirus Initiative, among others. The release of a new multiplex PCR kit by Roche for simultaneously detecting arboviruses in September 2025 and a portable Zika rapid test kit for use in tropical climates by Abbott in July 2025 serve as examples of the innovations driving market growth.

Market Size and Forecast:

• Study Period: 2022–2035

• Market Size (2026E): USD 1.37 Billion

• Market Size 2035: USD 2.01 Billion

• CAGR: 4.36% from 2026 to 2035

• Fastest Growing Region: Asia Pacific

• Largest Region: North America

To Get more information on Arbovirus Testing Market - Request Free Sample Report

Arbovirus Testing Market Trends:

• Accelerating development and adoption of multiplex molecular assay platforms capable of detecting dengue, Zika, chikungunya, and West Nile virus simultaneously in a single clinical sample, dramatically reducing diagnostic turnaround time during outbreak scenarios and improving clinical efficiency in co-endemic regions where multiple arboviruses circulate concurrently.

• Rising deployment of point-of-care rapid antigen and antibody test kits in resource-limited tropical and subtropical settings where laboratory RT-PCR infrastructure is unavailable, enabling front-line health workers to deliver arbovirus diagnosis at the community level and guide timely patient isolation and vector control responses.

• Growing integration of next-generation sequencing and digital PCR platforms into arbovirus reference laboratory workflows for viral variant surveillance, imported case investigation, and resistance monitoring, providing the genomic epidemiology data that national health authorities require for evidence-based outbreak response strategies.

• Increasing government and international health organization investment in integrated vector-borne disease surveillance networks combining environmental mosquito testing, genomic sequencing of circulating viral strains, and clinical diagnostic data to provide real-time arboviral transmission risk mapping for public health early warning systems.

U.S. Arbovirus Testing Market Size Outlook:

U.S. Arbovirus Testing Market was valued at approximately USD 0.52 Billion in 2025 and is expected to reach USD 0.78 Billion by 2035, growing at a CAGR of approximately 4.14%, driven by CDC arbovirus surveillance mandates, West Nile virus endemic circulation, returning international traveller testing demand, and growing investment in multiplex diagnostic platforms at major reference laboratories.

The United States maintains the largest single national arbovirus testing market, anchored by the CDC's well-funded national arboviral diseases surveillance programme, the endemic circulation of West Nile virus across all continental states, the country's status as one of the world's largest international travel destinations generating substantial imported dengue and Zika case volumes requiring clinical diagnosis, and the country's world-class molecular diagnostics industry whose investments in multiplex assay development are continuously expanding the clinical utility and cost-efficiency of arbovirus testing. The U.S. market's technical sophistication is reflected in the rapid adoption of the FDA's Emergency Use Authorization framework for novel arboviral assays during outbreak events, which accelerated domestic diagnostic availability for both Zika during the 2015-2016 pandemic and during subsequent dengue surges in Florida and Hawaii.

In September 2025, Roche introduced a new generation of multiplex PCR kits for concurrent testing of several types of arboviruses, thus improving outbreak prevention and screening programs for pregnant women at hospitals and reference laboratories in the United States and abroad. These innovations, alongside Abbott's introduction of a rapid Zika test kit in July 2025 that improved the stability of reagents in tropical regions for greater use in Latin America and Asia-Pacific, demonstrate the leadership of the U.S.-based diagnostics industry in innovations in arbovirus testing that will drive market growth until 2035.

Arbovirus Testing Market Segment Highlights

• By Test Type, ELISA-Based Tests dominated with approximately 49% revenue share in 2025 due to established clinical reliability, scalability, and cost-effectiveness for large-scale seroprevalence surveys; RT-PCR-Based Tests are expected to grow at the fastest CAGR through 2026 to 2035, driven by superior sensitivity, specificity, and early-infection detection capability making them the gold standard for acute arboviral diagnosis.

• By Pathogen, Dengue dominated with the highest revenue share in 2025 driven by its status as the world's most prevalent arboviral disease affecting over 400 million people annually; Zika is expected to grow fastest through 2026 to 2035, driven by expanded prenatal and travel screening programmes and sustained surveillance investment following the 2015-2016 pandemic.

• By End Use, Diagnostic Laboratories held the highest revenue share in 2025 due to high test volumes and advanced molecular platform deployment; Hospitals are expected to grow at a competitive CAGR driven by in-house rapid testing adoption for acute febrile illness management and point-of-care arboviral diagnosis at emergency and tropical medicine departments.

By Test Type, ELISA-Based Tests dominate, RT-PCR grows fastest

Tests based on the enzyme-linked immunosorbent assay (ELISA) were the top revenue generating category within the global market for arbovirus testing by type in 2025 with 49% share owing to its proven clinical value in diagnosing present and past arbovirus infections using antibodies and antigens, particularly IgM and IgG serological markers, which are essential for diagnosis and seroprevalence studies. The relatively low cost, high efficiency, and ability to process samples in bulk, in addition to being compatible with laboratory equipment already in place in most clinics, makes ELISA a preferred choice for diagnosing arbovirus infections in low- and middle-income countries, which form the bulk of global arbovirus cases. Innovations such as automated ELISA and bead-based multiplex immunoassay technology have enhanced the efficacy of the tests and made them more economical, thereby maintaining their commercial leadership.

Tests Based on RT-PCR will witness the highest CAGR between 2026 and 2035 due to their gold standard sensitivity and specificity for detecting early-infection viral RNA in the acute viraemic stage prior to the development of any antibodies – the most crucial stage for making decisions for clinical isolation and vector control during outbreaks. The multiplex PCR test kit introduced by Roche in September 2025, which is capable of diagnosing dengue, Zika, and chikungunya using a single sample, is the current industry best in RT-PCR arbovirus diagnostics that offers the efficiency required for the reference labs and tropical medicine departments within hospitals for efficient outbreak management.

By Pathogen, Dengue dominates, Zika grows fastest

The leading disease in the global market for Arbovirus Testing by Pathogen in 2025 was dengue, which had the largest revenue share due to its being the most common viral infection spread by mosquitoes around the world, with estimates of more than 400 million infections yearly and more than 100 countries where the disease is endemic. This is evidenced by the fact that according to the report released by the WHO in 2025, the number of dengue cases reported globally in the first half of the year is 6.8 million cases, a 24% rise compared to 2024. There are three clinical phases during which specific tests have to be carried out: NS1 antigen test during the acute febrile phase, IgM ELISA during the early convalescent phase, and IgG serology in the case of past infection.

Zika is expected to grow at the fastest CAGR through 2026 to 2035, driven by the global expansion of prenatal Zika screening programs mandating testing in pregnant women with travel history to endemic regions, the sustained investment in Zika diagnostic capacity by national health authorities maintaining post-pandemic surveillance readiness, and the geographic spread of Aedes aegypti vectors into previously non-endemic subtropical regions that is creating new potential transmission zones requiring preparedness-level testing infrastructure. Abbott's July 2025 launch of a portable Zika rapid test kit with tropical climate-optimized reagent stability for deployment in Latin American and Asia Pacific settings confirms major diagnostics companies' continued investment in Zika-specific diagnostic innovation.

Regional Analysis:

North America Arbovirus Testing Market Insights

North America dominated the global Arbovirus Testing Market in 2025 with approximately 42% of revenues, anchored by the United States' CDC-funded surveillance infrastructure, West Nile virus endemic presence, large returning international traveler testing volumes, and the concentration of the world's leading molecular diagnostics companies including Roche, Abbott, bioMerieux, and Hologic that are continuously advancing arbovirus assay sensitivity, multiplex capability, and automation. The U.S. regulatory framework's accelerated EUA pathway for novel arboviral diagnostics enables rapid deployment of new testing technologies during outbreak events.

Get Customized Report as per Your Business Requirement - Enquiry Now

Europe Arbovirus Testing Market Insights

Europe represents a growing arbovirus testing market where climate change is progressively expanding Aedes albopictus tiger mosquito habitats across Southern and Central European countries, creating new indigenous transmission risk for dengue and chikungunya in France, Italy, Spain, and the Balkans that is driving national arbovirus surveillance programme investment. Travel-associated arbovirus case detection in returning tourists from tropical destinations sustains laboratory testing volumes across Northern European reference hospital and public health laboratory networks year-round.

Asia Pacific Arbovirus Testing Market Insights

Asia Pacific is the fastest-growing region in the arbovirus testing market, projected to grow at the highest CAGR through 2026 to 2035, driven by the region's extraordinary endemic arboviral disease burden where dengue, Japanese encephalitis, and chikungunya circulate simultaneously across India, Southeast Asia, and the Western Pacific, generating the world's highest absolute arbovirus testing volumes. India and Southeast Asia's expanding diagnostic laboratory infrastructure investment, combined with the progressive rollout of national dengue surveillance programs requiring standardized serological testing, is creating sustained growth in test kit procurement volumes.

Middle East & Africa and Latin America Arbovirus Testing Market Insights

Latin America represents the second-largest regional arbovirus testing market driven by Brazil's exceptional arboviral disease burden where dengue, Zika, chikungunya, and yellow fever co-circulate, supporting large national diagnostic programmes anchored by the Brazilian Ministry of Health's surveillance infrastructure. MEA represents a developing but growing market, with the Arabian Peninsula's dengue endemicity in Yemen and Sudan, expanding Zika surveillance in sub-Saharan Africa, and improving laboratory infrastructure investments driving progressive arbovirus testing market development.

Market Dynamics:

Growth Drivers: Escalating global arboviral disease burden driven by climate change and urbanization creating structural demand for advanced testing solutions

The main structural factor driving the growth in the Arbovirus Testing Market is the promising epidemiological trend of rising global incidence rates of arboviral diseases, with the WHO reporting of 6.8 million dengue infections in the early years of 2025, which is a 24% YoY rise, indicating that the combination of climate change leading to increased habitat areas for mosquitoes, rapid urbanization contributing to more human-vector interactions, and travel allowing for the introduction of arboviral diseases into new areas is collectively posing a threat worldwide. Government-driven efforts, such as the WHO Global Arbovirus Initiative, CDC surveillance programs for vector-borne diseases, and national funding for emergency preparedness after the COVID-19 pandemic, are strengthening spending on diagnostics, thus fueling the testing market regardless of outbreaks.

In September 2025, Roche released a new generation of multiplex PCR kits that allow for concurrent testing of multiple arboviruses, thus satisfying the need for quick diagnostic tests for outbreak preparedness in co-endemic areas. Meanwhile, in July 2025, Abbott brought out a portable Zika rapid test kit with improved reagent stability suitable for use in tropical climates in Latin America and Asia Pacific. These developments by the two leading diagnostics companies illustrate the continuous commercial commitment to develop arbovirus testing platforms, which will continue to fuel the market until 2035.

Restraints: Cross-reactive serology, dengue serotype complexity, and diagnostic capacity gaps in resource-limited endemic settings constraining accurate case detection

A significant restraint on the Arbovirus Testing Market is the substantial diagnostic challenge posed by serological cross-reactivity between flaviviruses including dengue, Zika, and West Nile virus, where antibodies generated against one flavivirus can produce false-positive or indeterminate results on ELISA-based assays targeting related viruses, requiring expensive and technically demanding confirmatory testing that is unavailable in the resource-limited healthcare settings of most high-burden endemic countries. The four dengue serotypes' secondary infection hyperimmunity complexity further complicates diagnostic interpretation, as cross-reactive antibody responses in secondary infections can confound standard IgM and IgG ELISA interpretation and require plaque reduction neutralization tests available only at reference laboratories.

Opportunities: Multiplex point-of-care platform development, integrated environmental and clinical surveillance, and blood safety screening market expansion

The most transformative commercial opportunity in the arbovirus testing market is the development of affordable, accurate, multiplex point-of-care platforms that can simultaneously distinguish dengue, Zika, chikungunya, and malaria from non-specific febrile illness presentations at community health post and primary care settings in tropical countries, enabling targeted clinical management without requiring laboratory referral that delays treatment decisions by days in resource-limited settings. Blood safety screening represents a high-value and growing market opportunity as national blood transfusion services in dengue-endemic countries including Brazil, India, Thailand, and the Philippines are implementing mandatory arboviral nucleic acid testing for blood donations to prevent transfusion-transmitted arboviral disease, creating sustained institutional procurement for sensitive RT-PCR and nucleic acid amplification screening assays.

Recent Developments:

• September 2025: Roche announced the launch of a next-generation multiplex PCR kit designed for simultaneous detection of multiple arboviruses including dengue, Zika, and chikungunya in a single clinical sample, enhancing outbreak preparedness and maternal health screening capabilities at hospital and reference laboratory settings across endemic and non-endemic regions globally.

• July 2025: Abbott introduced a portable Zika rapid test kit with enhanced reagent stability specifically engineered for tropical climate deployment conditions, aimed at expanding diagnostic access for Zika virus detection in resource-limited healthcare settings across Latin America and Asia Pacific where standard laboratory refrigeration infrastructure is unreliable.

Arbovirus Testing Market Key Players:

• Roche Diagnostics

• Abbott Laboratories

• bioMerieux S.A.

• Hologic Inc.

• Thermo Fisher Scientific

• Bio-Rad Laboratories

• Qiagen N.V.

• SD Biosensor Inc.

• InBios International Inc.

• Eurofins Scientific

• Altona Diagnostics GmbH

• RealStar (altona)

• Biopanda Reagents

• CTK Biotech Inc.

• OraSure Technologies

• Vela Diagnostics

• Luminex Corporation (DiaSorin)

• Siemens Healthineers

• Novabay Pharmaceuticals

• Chembio Diagnostics